Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Dimitrios Doultsinos, a John Black Research Fellow in Prostate Oncology at Oxford University's Nuffield Department of Surgical Sciences (NDS), was one of this year’s recipients of the highly coveted Prostate Cancer Foundation (PCF) Young Investigator Award.

Dimitrios Doultsinos in front of lab bench

PCF Young Investigator Awards are intended to identify a cohort of future research leaders who will keep the field of prostate cancer research vibrant with new ideas and offer career and project support for early career physicians and scientists who are committed to advancing the prostate cancer field. Thirty-four PCF Young Investigator Awards totaling $7.2 million were granted to the promising next generation of cancer researchers.

Joining the PCF community instantly opens up a wealth of collaborative opportunities which will enrich the support network that NDS provides me as a young investigator to produce clinically relevant scientific results
- Dr Dimitrios Doultsinos

Dr Doultsinos received the 2022 CRIS Cancer Foundation, Eustace Wolfington and Larry Leeds – PCF Young Investigator Award for his project, 'Exploring Synthetic Lethality of Targeting miR346-Unfolded Protein Response Dependent DNA Damage Response Mechanisms in Treatment-Resistant Prostate Cancer'.

Altered stress response pathways are a hallmark of cancer which allows tumour cells to rapidly grow and avoid normal death signals; however, these alterations may also create sensitivities that can be therapeutically targeted.

The award will provide support for Dr Doultsinos to investigate the biology of the unfolded protein response in prostate cancer. He will determine whether these alterations may act as biomarkers for sensitivity to certain treatments, or may be promising therapeutic targets themselves.

“I feel privileged to win a PCF Young Investigator Award, joining an extremely talented class of 2022," said Dr Doultsinos. "Joining the PCF community instantly opens up a wealth of collaborative opportunities which will enrich the support network that NDS provides me as a young investigator to produce clinically relevant scientific results.

"Bring on accelerating prostate cancer research with the support of CRIS Cancer Foundation, NDS, Imperial College London and my mentors Professor Ian Mills and Dr Claire Fletcher."

Read more about Dr Doultsinos's research and the PCF Young Investigator Awards on the Prostate Cancer Foundation website. 

The Class of 2022 recipients at the PCF Young Investigator Award ceremony. Dr Dimitrios Doultsinos stands centre stage.

Dimitrious Doultsinos (centre) on stage with the other recipients at the 2022 PCF Young Investigator Award ceremony.

Howard Soule (PCF CSO and Executive Vice President) and Dimitrious Doultsinos at the PCF Young Investigator Award ceremony

Howard Soule (PCF Chief Science Officer and Executive Vice President) and Dimitrious Doultsinos.